ArticleFrontiers in immunology2026
Clinical implications of plasma sADAM10: integrating renal function, histopathology and prognostic outcomes in chronic kidney disease and kidney transplantation.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The identification of novel non-invasive biomarkers is crucial for improving the management of chronic kidney disease (CKD) and kidney transplant recipients (KTR). While A Disintegrin and Metalloprotease 10 (ADAM10) is involved in kidney pathology, the clinical relevance of its soluble form, soluble ADAM10 (sADAM10), remains poorly defined. Methods: In this retrospective cohort study, we enrolled 488 participants, including 145 kidney transplant recipients (KTR), 295 patients with chronic kidney disease (CKD), and 48 healthy controls (HC). Plasma sADAM10 was measured by ELISA and evaluated for its correlation with renal function, laboratory parameters, and histopathological findings. Its prognostic value for adverse outcomes was determined using Kaplan-Meier analyses, restricted cubic spline (RCS) Cox regression, and incremental value assessment. Results: Plasma sADAM10 were significantly elevated in biopsy-proven KTR and CKD patients compared to HC. Multivariate analyses revealed cohort-specific independent associations: plasma sADAM10 was independently associated with eGFR in CKD (standardized β = -0.24, P < 0.001), but with neutrophil count in KTR (standardized β = 0.24, P = 0.034). Histopathologically, higher plasma sADAM10 were associated with the severity of interstitial fibrosis and tubular atrophy (IFTA), tubular injury, and interstitial inflammation. RCS analysis demonstrated a significant non-linear association between plasma sADAM10 and post-transplant infection risk (P for non-linearity = 0.029), with plasma sADAM10 providing incremental prognostic value beyond age and eGFR (C-index increase from 0.795 to 0.842; likelihood ratio P = 0.005). In contrast, after adjusting for eGFR and proteinuria, plasma sADAM10 showed no independent association with the composite renal endpoint. For patients with advanced CKD, plasma sADAM10 concentration showed an exponential association with the predicted 5-year risk of kidney failure. Conclusion: Plasma sADAM10 is a context-dependent biomarker with endpoint-specific prognostic value. It shows an independent association with renal dysfunction in CKD and inflammatory activation in KTR, and predicts post-transplant infection risk with incremental value beyond traditional markers. However, its apparent association with renal outcomes is confounded by eGFR. These findings highlight the potential of plasma sADAM10 for infection risk stratification in KTR and warrant further validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.